Brief: CEL-SCI Corporation announces Phase 3 Multikine® head and neck cancer results posted on clinicaltrials.gov
Brief: Cel-Sci Corp Reports Quarterly Loss Per Share $0.23
Brief: CEL-SCI Corp Posts Qtrly Loss Per Share Of $0.66
Brief: Cel-Sci Appoints Dr. Gail Naughton To Its Board Of Directors
Brief: Cel-Sci Corp Files For Mixed Shelf Of Upto $150 Million
Brief: Cel-Sci Presents Phase 3 Multikine Head And Neck Cancer Data
Brief: Cel-Sci Corporation Reports Second Quarter Fiscal 2022 Financial Results
CEL-SCI jumps after report on private call comments
Amex Resumed Cel: SCI CORP ORD
AMEX HALT ADDITIONAL INFORMATION LAST 5.780000
Brief: Cel-Sci Corporation Reports First Quarter Fiscal 2022 Financial Results
CEL-SCI Corp shares tumble after drug trial update
Amex Resumed Cel: SCI CORP ORD
AMEX HALT ADDITIONAL INFORMATION LAST 15.560000
Amex Resumed Cel: SCI CORP ORD
AMEX HALT ADDITIONAL INFORMATION LAST 12.110000
Amex Resumed Cel: SCI CORP ORD
AMEX HALT ADDITIONAL INFORMATION LAST 10.960000
Amex Resumed Cel: SCI CORP ORD